Teva

AdhereTech Announces Appointment of Paul Sekhri to Board of Directors

Retrieved on: 
Wednesday, February 21, 2024

SUMMIT, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- AdhereTech, Inc., the market leading provider of real-time medication adherence solutions proven to help patients remain on their medications longer, improving patient outcomes and pharma company revenue, today announces that long-time life sciences industry executive, Paul Sekhri, has joined the Board of Directors, effective February 7, 2024.

Key Points: 
  • SUMMIT, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- AdhereTech, Inc., the market leading provider of real-time medication adherence solutions proven to help patients remain on their medications longer, improving patient outcomes and pharma company revenue, today announces that long-time life sciences industry executive, Paul Sekhri, has joined the Board of Directors, effective February 7, 2024.
  • “We are excited to have Paul join the AdhereTech Board of Directors,” commented Neale Trangucci, Chair of the Board.
  • Paul Sekhri added: “I welcomed the opportunity to join the Board of AdhereTech as I see that the company’s Aidia real-time adherence technology can effectively address a major issue - non-adherence to medication.
  • I look forward to working with my fellow Board members and the management team to help ensure AdhereTech’s solutions get to those who need them.”

Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China

Retrieved on: 
Monday, February 26, 2024

The partnership intends to increase patients’ access to Teva’s AUSTEDO, leveraging Nhwa’s leadership in China’s neuro-psychiatric health sector.

Key Points: 
  • The partnership intends to increase patients’ access to Teva’s AUSTEDO, leveraging Nhwa’s leadership in China’s neuro-psychiatric health sector.
  • “Nhwa has deep neuro-psychiatry expertise and capabilities, from research and development to commercialization,” commented Theodor Wee, General Manager of Teva Greater China.
  • Chorea, one of the most striking physical manifestations of Huntington’s disease, is a neurological disorder that causes involuntary, random muscle movements.
  • Jiangsu Nhwa Pharmaceutical Co., Ltd., founded in 1978, is a leading CNS company in China.

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

Retrieved on: 
Saturday, February 24, 2024

Teva is Alvotech’s strategic partner for the exclusive commercialization of SIMLANDI in the United States.

Key Points: 
  • Teva is Alvotech’s strategic partner for the exclusive commercialization of SIMLANDI in the United States.
  • An interchangeable biosimilar may be substituted at the pharmacy without consulting the prescriber, much like generic drugs are routinely substituted for brand name drugs.
  • As the only interchangeable adalimumab biosimilar with the high-concentration formulation, SIMLANDI can be substituted for Humira at the pharmacy level, subject to state pharmacy laws.
  • Alvotech handles development and manufacturing, and Teva is responsible for U.S. commercialization, which leverages Teva’s extensive experience and sales and marketing infrastructure.

Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting

Retrieved on: 
Tuesday, February 20, 2024

“These results from the first-in-human trials of anti-TL1A (TEV-’574) are exciting because they show that it effectively engages with the TL1A target, supports its safety profile and is well-tolerated.

Key Points: 
  • “These results from the first-in-human trials of anti-TL1A (TEV-’574) are exciting because they show that it effectively engages with the TL1A target, supports its safety profile and is well-tolerated.
  • “We are currently investigating the efficacy and safety of anti-TL1A (TEV-’574) in IBD through the RELIEVE UCCD Phase 2 trial, which features an innovative and efficient basket study design allowing the inclusion of patients with either type of IBD (ulcerative colitis and Crohn’s disease).
  • Each company will equally share the development costs globally and net profits and losses in major markets, with other markets subject to a royalty arrangement, and Sanofi will lead the development of the Phase 3 program.
  • Teva will lead commercialization of the product in Europe, Israel and specified other countries, and Sanofi will lead commercialization in North America, Japan, other parts of Asia and the rest of the world.

Teva Celebrates 40th Anniversary with the Launch of its 'Where to Next?' Campaign

Retrieved on: 
Wednesday, February 28, 2024

GOLETA, Calif., Feb. 28, 2024 /PRNewswire/ -- Teva®, a division of Deckers Brands (NYSE: DECK), announces its 'Where to Next?' campaign in celebration of the brand's 40th anniversary and the creation of the sport sandal category.

Key Points: 
  • GOLETA, Calif., Feb. 28, 2024 /PRNewswire/ -- Teva ®, a division of Deckers Brands (NYSE: DECK), announces its 'Where to Next?'
  • campaign in celebration of the brand's 40th anniversary and the creation of the sport sandal category.
  • For the last four decades, Teva has fueled exploration and the freedom to roam, leaving footprints all over the world.
  • campaign along with the unveiling of a four-part 'Revive' product series inspired by the '80s, '90s, '00s and '10s.

Global Healthcare Executive Jill DeSimone Joins Swim Across America Board of Directors

Retrieved on: 
Thursday, February 15, 2024

CHARLOTTE, N.C., Feb. 15, 2024 /PRNewswire-PRWeb/ -- Swim Across America, a national nonprofit dedicated to providing grants for cancer research and patient programs and raising funds through swimming events, is pleased to announce that Jill DeSimone, a global pharmaceutical executive, has been appointed to the Swim Across America Board of Directors. Jill's career included championing excellence in patient care for serious diseases, while igniting scalable growth and agility in the healthcare marketplace. She held positions of executive leadership for more than 30 years, culminating in eight years as president of Oncology for Merck.

Key Points: 
  • After a Successful Career with Oncology Pharmaceutical Companies, Jill DeSimone is Making Waves in the Fight Against Cancer
    CHARLOTTE, N.C., Feb. 15, 2024 /PRNewswire-PRWeb/ -- Swim Across America , a national nonprofit dedicated to providing grants for cancer research and patient programs and raising funds through swimming events, is pleased to announce that Jill DeSimone, a global pharmaceutical executive, has been appointed to the Swim Across America Board of Directors.
  • "One of my greatest joys has been volunteering and encouraging many of my colleagues and friends to volunteer with Swim Across America," says Jill DeSimone.
  • "Jill has been supporting Swim Across America for many years," commented Pam Ryan, Swim Across America board chair.
  • Swim Across America was founded in 1987 with its first open water charity swim in Long Island Sound.

MedinCell’s partner Teva Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK / Olanzapine Long-Acting Injectable (LAI)

Retrieved on: 
Tuesday, January 9, 2024

Results of the study are expected in the second half of 2024.1

Key Points: 
  • Results of the study are expected in the second half of 2024.1
    mdc-TJK is an investigational once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine for the treatment of schizophrenia.
  • It has the potential to be the first long-acting olanzapine with a favorable safety profile.2
    Teva remains fully responsible to lead the development and commercialization of olanzapine LAI globally.
  • 1 Full webcast of Teva’s presentation at 42nd Annual J.P. Morgan Healthcare Conference, January 8, 2024 is available on ir.tevapharm.com .
  • 2 The only existing LAI of Olanzapine has a FDA black box warning from for PDSS (Post injection Delirium/Sedation Syndrome) that limits its use.

Sterne Kessler Secures Non-Infringement Win for Teva Pharmaceuticals

Retrieved on: 
Friday, January 5, 2024

WASHINGTON, Jan. 5, 2024 /PRNewswire/ -- Sterne, Kessler, Goldstein & Fox secured a victory on behalf of Teva Pharmaceuticals in the U.S. Court District Court for the District of New Jersey in a case involving a patent-infringement suit filed by Corcept Therapeutics.

Key Points: 
  • WASHINGTON, Jan. 5, 2024 /PRNewswire/ -- Sterne, Kessler, Goldstein & Fox secured a victory on behalf of Teva Pharmaceuticals in the U.S. Court District Court for the District of New Jersey in a case involving a patent-infringement suit filed by Corcept Therapeutics.
  • On December 29, 2023, the district court held that Teva does not infringe the two patents asserted at trial, finding that Corcept had failed to show that direct infringement is likely or that Teva's label would induce infringement.
  • Teva Pharmaceuticals USA, Inc. is a leading manufacturer of generic and proprietary drug products.
  • Corcept Therapeutics, Inc., the holder of the Korlym NDA, filed a Hatch-Waxman lawsuit against Teva alleging infringement of two patents listed in the Orange Book for Korlym.

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance at 8 a.m. ET on January 31, 2024

Retrieved on: 
Tuesday, January 2, 2024

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2023 financial results, as well as on its financial guidance for 2024, on Wednesday, January 31, 2024, at 7:00 a.m.

Key Points: 
  • Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2023 financial results, as well as on its financial guidance for 2024, on Wednesday, January 31, 2024, at 7:00 a.m.
  • Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m.
  • In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin.
  • A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations
    Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva's website.

Human medicines European public assessment report (EPAR): Dimethyl fumarate Teva, dimethyl fumarate, Date of authorisation: 12/12/2022, Date of refusal: 12/12/2023, Status: Withdrawn

Retrieved on: 
Tuesday, January 2, 2024

Select 'available languages' to access the language you need.

Key Points: 
  • Select 'available languages' to access the language you need.
  • Product information documents contain:
    - summary of product characteristics (annex I);
    - manufacturing authorisation holder responsible for batch release (annex IIA);
    - conditions of the marketing authorisation (annex IIB);
    - labelling (annex IIIA);
    - package leaflet (annex IIIB).
  • Dimethyl fumarate Teva: EPAR - All authorised presentations
    Product details
    - Name of medicine
    - Dimethyl fumarate Teva
    - Active substance
    - dimethyl fumarate
    - International proprietary name (INN) or common name
    - dimethyl fumarate
    - Therapeutic area (MeSH)
    - Multiple Sclerosis, Relapsing-Remitting
    - Multiple Sclerosis
    - Anatomical therapeutic chemical (ATC) code
    - L04AX07
    Pharmacotherapeutic groupImmunosuppressants
    Therapeutic indication
    Dimethyl fumarate Teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS).
  • Assessment history
    This page was last updated on